Adoption of GeneStrat by oncologists is helping to drive greater adoption of VeriStrat, Biodesix's proteomic test for assessing a patient's prognosis and predicting response to drug treatment.
The results on this study are particularly exciting, as they suggest that we may be able to identify patients most likely to benefit from anti-PD-1 therapies.
Biodesix listed at 216 in the Inc500 for 2015
Genestrat: a targeted liquid biopsy for patients with NSCLC. Blood test with 72 hour turnaround time.
Biodesix' VeriStrat test has won approval and coverage from United HealthCare.
Study: better NSCLC outcomes with proteomic test
Results from a analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Biodesix in Nature - Proteomic technology
Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.
Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.